VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback